GSK3A and Alzheimer disease: Furthermore, although several GSK3α/β inhibitors were developed (Fronza et al., 2023; Li et al., 2023), the applications of these inhibitors for AD therapy remain unreachable because of their large molecular weight, serious side effects, low efficacy, among others (Wei et al., 2022).